MedPath

A phase 2 study of cisplatin plus pemetrexed followed by maintenance pemetrexed in unresectable malignant pleural mesothelioma

Not Applicable
Recruiting
Conditions
malignant pleural mesothelioma
Registration Number
JPRN-UMIN000015226
Lead Sponsor
Kyoto Thoracic Oncology Research Group
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
45
Inclusion Criteria

Not provided

Exclusion Criteria

1) With interstitial pneumonitis or pulmonary fibrosis which chest X-P can detect 2) With fluid accumulation which shoud be treated 3) With active double cancer 4) Patients who had already undergone cisplatin or pemetrexed 5) With poor-controled diabetes mellitus or hypertension 6) With liver cirrhosis diagnosed by imaging findings or clinical findings 7) History of severe heart disease (acute cardiac infarction or unstable angina within 6 months of registration, post-PTCA, post-CABG, sign of heart failure, uncontrollable arrythmia) 8) History of active infection 9) History of pregnancy or lactation 10) Sever drug allergy 11) No consent to blood transfusion 12) Evidence of bleeding tendency 13) No premedication of pemetrexed 14) Those judged to be not suitable by the attending physician

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
progression free survival from induction therapy
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath